Canada Markets close in 5 hrs 18 mins
  • S&P/TSX

    18,719.88
    -358.76 (-1.88%)
     
  • S&P 500

    3,753.44
    -65.39 (-1.71%)
     
  • DOW

    30,553.49
    -475.82 (-1.53%)
     
  • CAD/USD

    0.7745
    -0.0011 (-0.1425%)
     
  • CRUDE OIL

    105.90
    -3.88 (-3.53%)
     
  • BTC-CAD

    24,550.97
    -1,523.21 (-5.84%)
     
  • CMC Crypto 200

    407.12
    -24.35 (-5.64%)
     
  • GOLD FUTURES

    1,812.60
    -4.90 (-0.27%)
     
  • RUSSELL 2000

    1,685.17
    -34.20 (-1.99%)
     
  • 10-Yr Bond

    3.0200
    -0.0730 (-2.36%)
     
  • NASDAQ

    10,919.33
    -258.56 (-2.31%)
     
  • VOLATILITY

    30.19
    +2.03 (+7.21%)
     
  • FTSE

    7,124.00
    -188.32 (-2.58%)
     
  • NIKKEI 225

    26,393.04
    -411.56 (-1.54%)
     
  • CAD/EUR

    0.7427
    +0.0002 (+0.03%)
     

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc

DUBLIN, Ireland, May 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 9, 2022, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2022.

To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 8183841. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting